Rosemary Crane Net Worth

The estimated Net Worth of Rosemary A Crane is at least 426 千$ dollars as of 24 June 2024. Ms. Crane owns over 3,350 units of Teva- Pharmaceutical Industries stock worth over 96,086$ and over the last 7 years she sold TEVA stock worth over 0$. In addition, she makes 329,999$ as Independent Director at Teva- Pharmaceutical Industries.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Crane TEVA stock SEC Form 4 insiders trading

Rosemary has made over 12 trades of the Teva- Pharmaceutical Industries stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 3,350 units of TEVA stock worth 60,166$ on 24 June 2024.

The largest trade she's ever made was exercising 21,108 units of Teva- Pharmaceutical Industries stock on 15 June 2024 worth over 379,100$. On average, Rosemary trades about 3,584 units every 54 days since 2017. As of 24 June 2024 she still owns at least 5,350 units of Teva- Pharmaceutical Industries stock.

You can see the complete history of Ms. Crane stock trades at the bottom of the page.

Rosemary Crane biography

Rosemary A. Crane serves as Independent Director of the Company. Ms. Crane served as President and Chief Executive Officer of MELA Sciences, Inc. from 2013 to 2014. Ms. Crane was Head of Commercialization and a partner at Appletree Partners from 2011 to 2013. From 2008 to 2011, she served as President and Chief Executive Officer of Epocrates Inc. Ms. Crane served in various senior executive positions at Johnson & Johnson from 2002 to 2008, including as Group Chairman, OTC & Nutritional Group from 2006 to 2008, as Group Chairman, Consumer, Specialty Pharmaceuticals and Nutritionals from 2004 to 2006, and as Executive Vice President of Global Marketing for the Pharmaceutical Group from 2002 to 2004. Prior to that, she held various positions at Bristol-Myers Squibb from 1982 to 2002, including as President of U.S. Primary Care from 2000 to 2002 and as President of Global Marketing and Consumer Products from 1998 to 2000. Ms. Crane has served on the board of directors of Catalent Pharma Solutions, Inc. since 2018. From 2015 to 2019, she served as Vice Chairman of the Board of Zealand Pharma A/S. From 2017 to March 2019, she served on the board of directors of Edge Therapeutics.

What is the salary of Rosemary Crane?

As the Independent Director of Teva- Pharmaceutical Industries, the total compensation of Rosemary Crane at Teva- Pharmaceutical Industries is 329,999$. There are 15 executives at Teva- Pharmaceutical Industries getting paid more, with Kaare Schultz having the highest compensation of 11,596,600$.

How old is Rosemary Crane?

Rosemary Crane is 60, she's been the Independent Director of Teva- Pharmaceutical Industries since 2015. There are 6 older and 22 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.

What's Rosemary Crane's mailing address?

Rosemary's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.

Insiders trading at Teva- Pharmaceutical Industries

Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over 31,332,399$ worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth 16,473,820$ . The most active insiders traders include Sol J Barer、Tal Zvi Zaks、Roberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of 636,538$. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth 231,181$.

What does Teva- Pharmaceutical Industries do?

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Complete history of Ms. Crane stock trades at Catalent、Teva- Pharmaceutical Industries、Tarsus Pharmaceuticals、Certara

Teva- Pharmaceutical Industries executives and stock owners

Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:

• Kaare Schultz,
  President, Chief Executive Officer, Director
• Kare Schultz,
  Pres, CEO & Director
• Mark Sabag,
  Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
• Hafrun Fridriksdottir,
  Executive Vice President - Global R&D
• Brendan O'Grady,
  Executive Vice President - North America Commercial
• Gianfranco Nazzi,
  Executive Vice President - International Markets Commercial
• Dr. Hafrun Fridriksdottir,
  Exec. VP of Global R&D
• Gianfranco Nazzi,
  Exec. VP of International Markets Commercial
• Eric Drape,
  Exec. VP of Global Operations
• Eliyahu Sharon Kalif,
  Exec. VP & CFO
• Sol Barer,
  Independent Chairman of the Board
• Nechemia Peres,
  Independent Director
• Gerald Lieberman,
  Independent Director
• Amir Elstein,
  Independent Director
• Roberto Mignone,
  Independent Director
• Rosemary Crane,
  Independent Director
• Jean-Michel Halfon,
  Independent Director
• Perry Nisen,
  Independent Director
• Ronit Satchi-Fainaro,
  Independent Director
• Eliyahu Kalif,
  Chief Financial Officer, Executive Vice President
• Kevin Mannix,
  Senior Vice President, Investor Relations
• Janet Vergis,
  Independent Director
• Abbas Hussain,
  Independent Director
• David Stark,
  Executive Vice President, Chief Legal Officer
• Eric Drape,
  Executive Vice President - Global Operations
• Sven Dethlefs,
  Executive Vice President - Global Marketing & Portfolio
• Richard Daniell,
  Executive Vice President - European Commercial
• Eli Shani,
  Exec. VP of Global Marketing & Portfolio
• Galia Inbar,
  Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG
• David M. Stark,
  Exec. VP & Chief Legal Officer
• Amir Weiss,
  Sr. VP & Chief Accounting Officer
• Lori Queisser,
  Sr. VP & Global Compliance Officer
• Andrew J. Weil CPA,
  Chief Accounting Officer
• Eric Drapé,
  Exec. VP of Global Operations
• Iris Beck Codner,
  EVP Global Brand&Communication
• Kare Schultz,
  President and CEO
• Michael James Mc Clellan,
  EVP, Chief Financial Officer
• Notaristefani Carlo De,
  Executive VP Global Operations
• Placid Jover,
  See "Remarks"
• Deborah A Griffin,
  Chief Accounting Officer
• Varda Shalev,
  
• Dan S Suesskind,
  Director
• Murray A Goldberg,
  Director
• Dov Bergwerk,
  Acting Chief Legal Officer
• David R. Mc Avoy,
  EVP, Chief Legal Officer
• Andrew Weil,
  Chief Accounting Officer
• Galia Inbar,
  See "Remarks"
• Eli Shani,
  EVP,Global Marketing&Portfolio
• Angus Grant,
  EVP, Business Development
• Eric A Hughes,
  See "Remarks"
• Vikki L Conway,
  See "Remarks"
• Christine Fox,
  EVP, Head of U.S. Commercial
• Amir Weiss,
  Chief Accounting Officer
• Richard D Francis,
  President and CEO
• Matthew Shields,
  EVP, Global Operations
• Tal Zvi Zaks,